Compare Stocks: SLXN, SKYE, CODX, and ALZN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALZN Alzamend Neuro	$1.70	$1.38	$0.84 ▼ $2.68	$8.20M	0.23	103,223 shs	128,246 shs
CODX Co-Diagnostics	$1.16	$1.91	$0.94 ▼ $46.50	$8.10M	2.85	352,961 shs	96,596 shs
SKYE Skye Bioscience	$1.78 -3.3%	$4.19	$1.64 ▼ $39.92	$8.15M	2.9	179,567 shs	21,035 shs
SLXN Silexion Therapeutics	$0.35 +0.1%	$1.66	$0.35 ▼ $77.70	$1.95M	-0.36	601,227 shs	125,955 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALZN Alzamend Neuro	0.00%	+2.10%	+17.24%	+53.15%	-27.97%
CODX Co-Diagnostics	0.00%	-7.94%	-23.38%	-79.40%	-88.24%
SKYE Skye Bioscience	-3.26%	-8.72%	-61.30%	-69.65%	-93.38%
SLXN Silexion Therapeutics	+0.11%	-2.39%	-81.49%	-92.47%	-99.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALZN Alzamend Neuro	$1.70	$1.38	$0.84 ▼ $2.68	$8.20M	0.23	103,223 shs	128,246 shs
CODX Co-Diagnostics	$1.16	$1.91	$0.94 ▼ $46.50	$8.10M	2.85	352,961 shs	96,596 shs
SKYE Skye Bioscience	$1.78 -3.3%	$4.19	$1.64 ▼ $39.92	$8.15M	2.9	179,567 shs	21,035 shs
SLXN Silexion Therapeutics	$0.35 +0.1%	$1.66	$0.35 ▼ $77.70	$1.95M	-0.36	601,227 shs	125,955 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALZN Alzamend Neuro	0.00%	+2.10%	+17.24%	+53.15%	-27.97%
CODX Co-Diagnostics	0.00%	-7.94%	-23.38%	-79.40%	-88.24%
SKYE Skye Bioscience	-3.26%	-8.72%	-61.30%	-69.65%	-93.38%
SLXN Silexion Therapeutics	+0.11%	-2.39%	-81.49%	-92.47%	-99.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALZN Alzamend Neuro	2.00	Hold	$28.00	1,547.06% Upside
CODX Co-Diagnostics	2.50	Moderate Buy	$67.50	5,718.97% Upside
SKYE Skye Bioscience	2.20	Hold	$64.00	3,495.51% Upside
SLXN Silexion Therapeutics	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest SLXN, SKYE, CODX, and ALZN Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/31/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
8/27/2026	SKYE Skye Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	CODX Co-Diagnostics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/17/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/3/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/29/2026	SLXN Silexion Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/20/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/10/2026	SKYE Skye Bioscience	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/29/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
6/15/2026	SLXN Silexion Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/11/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	$0.19 per share	N/A
CODX Co-Diagnostics	$620K	13.06	N/A	N/A	$1.82 per share	0.64
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	($0.11) per share	N/A
SLXN Silexion Therapeutics	N/A	N/A	N/A	N/A	$0.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALZN Alzamend Neuro	-$8.77M	-$2.90	N/A	N/A	N/A	N/A	-277.74%	-200.07%	9/9/2026 (Estimated)
CODX Co-Diagnostics	-$46.90M	-$10.32	N/A	N/A	N/A	-6,531.77%	-210.99%	-174.97%	11/5/2026 (Estimated)
SKYE Skye Bioscience	-$55.92M	-$10.16	N/A	N/A	N/A	N/A	-329.08%	-201.79%	N/A
SLXN Silexion Therapeutics	-$11.91M	-$42.47	N/A	N/A	N/A	N/A	-563.11%	-201.73%	11/11/2026 (Estimated)

Latest SLXN, SKYE, CODX, and ALZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/9/2026	Q1 2027	ALZN Alzamend Neuro	-$0.56	N/A	N/A	N/A	N/A	N/A
8/15/2026	Q2 2026	SLXN Silexion Therapeutics	-$21.20	-$5.17	+$16.03	-$5.17	N/A	N/A
8/14/2026	Q2 2026	SKYE Skye Bioscience	-$0.29	-$0.27	+$0.02	-$2.4550	N/A	N/A
8/13/2026	Q2 2026	CODX Co-Diagnostics	-$3.00	-$1.46	+$1.54	-$1.46	$0.13 million	$0.17 million
7/22/2026	Q4 2026	ALZN Alzamend Neuro	-$0.67	-$0.74	-$0.07	-$0.74	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	N/A
CODX Co-Diagnostics	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A
SLXN Silexion Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALZN Alzamend Neuro	N/A	1.31	1.31
CODX Co-Diagnostics	N/A	1.81	1.52
SKYE Skye Bioscience	N/A	0.95	0.95
SLXN Silexion Therapeutics	N/A	0.94	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALZN Alzamend Neuro	49.61%
CODX Co-Diagnostics	14.99%
SKYE Skye Bioscience	21.09%
SLXN Silexion Therapeutics	10.95%

Insider Ownership

Company	Insider Ownership
ALZN Alzamend Neuro	1.39%
CODX Co-Diagnostics	2.30%
SKYE Skye Bioscience	6.20%
SLXN Silexion Therapeutics	0.77%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALZN Alzamend Neuro	4	4.83 million	4.76 million	No Data
CODX Co-Diagnostics	100	6.98 million	6.82 million	No Data
SKYE Skye Bioscience	11	4.43 million	4.15 million	Optionable
SLXN Silexion Therapeutics	N/A	5.56 million	5.52 million	N/A

SLXN, SKYE, CODX, and ALZN Headlines

Recent News About These Companies

After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)

August 25, 2026 | markets.businessinsider.com

Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 14, 2026 | globenewswire.com

Silexion Therapeutics Prices $2.5 Million Securities Offering; Shares Down Pre-Bell

August 12, 2026 | finance.yahoo.com

Silexion Therapeutics Prices $2.5 Million Public Offering of Ordinary Shares and Warrants

August 11, 2026 | quiverquant.comQ

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

August 11, 2026 | globenewswire.com

Immunotherapy's Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN)

August 10, 2026 | markets.businessinsider.com

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

August 4, 2026 | finance.yahoo.com

Silexion Therapeutics Reports Preclinical Data Showing SIL204 Immune-Sensitizing Effects in KRAS-Mutant Cancer Cells

August 4, 2026 | quiverquant.comQ

Silexion Therapeutics Announces Board Member Resignation

July 31, 2026 | tipranks.com

Silexion Therapeutics Initiates Phase 2/3 Trial for Pancreatic Cancer Drug Candidate

July 30, 2026 | finance.yahoo.com

Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)

July 29, 2026 | markets.businessinsider.com

Silexion Therapeutics initiates phase 2/3 trial of SIL204 in pancreatic cancer

July 29, 2026 | msn.com

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center

July 29, 2026 | globenewswire.com

Silexion Therapeutics

July 21, 2026 | fool.com

Silexion Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:SLXN

July 1, 2026 | benzinga.com

Silexion Therapeutics Receives BfArM Approval to Initiate Phase 2/3 SIL204 Trial in Germany

June 23, 2026 | quiverquant.comQ

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

June 23, 2026 | globenewswire.com

Silexion Therapeutics to Attend BIO International Convention 2026

June 16, 2026 | globenewswire.com

Silexion Therapeutics Corp Ord Stock Short Interest Falls to 43.76%

June 10, 2026 | quiverquant.comQ

Silexion Therapeutics Corp: Silexion Therapeutics Announces 1-for-10 Reverse Share Split

May 26, 2026 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN, SKYE, CODX, and ALZN Company Descriptions

Alzamend Neuro NASDAQ:ALZN

$1.70 0.00 (0.00%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$1.68 -0.01 (-0.88%)

As of 05:38 AM Eastern

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Co-Diagnostics NASDAQ:CODX

$1.16 0.00 (0.00%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$1.16 0.00 (-0.09%)

As of 04:33 AM Eastern

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Skye Bioscience NASDAQ:SKYE

$1.78 -0.06 (-3.26%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$1.87 +0.09 (+5.06%)

As of 05:34 AM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Silexion Therapeutics NASDAQ:SLXN

$0.35 +0.00 (+0.11%)

Closing price 09/3/2026 04:00 PM Eastern

Extended Trading

$0.36 +0.01 (+2.96%)

As of 05:28 AM Eastern

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLXN, SKYE, CODX, and ALZN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLXN, SKYE, CODX, and ALZN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLXN, SKYE, CODX, and ALZN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN, SKYE, CODX, and ALZN Company Descriptions

Alzamend Neuro NASDAQ:ALZN

Co-Diagnostics NASDAQ:CODX

Skye Bioscience NASDAQ:SKYE

Silexion Therapeutics NASDAQ:SLXN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLXN, SKYE, CODX, and ALZN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLXN, SKYE, CODX, and ALZN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLXN, SKYE, CODX, and ALZN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLXN, SKYE, CODX, and ALZN Company Descriptions

Alzamend Neuro NASDAQ:ALZN

Co-Diagnostics NASDAQ:CODX

Skye Bioscience NASDAQ:SKYE

Silexion Therapeutics NASDAQ:SLXN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools